Global Med Technologies(R), Inc. Partners With Biomedical Synergies to Offer Advanced Tissue Tracking Solutions for Hospitals an
November 04 2008 - 9:00AM
PR Newswire (US)
Proven human tissue/implant tracking solution now available
internationally DENVER, Nov. 4 /PRNewswire-FirstCall/ -- Global Med
Technologies(R), Inc. ("Global Med") (OTC:GLOB) (BULLETIN BOARD:
GLOB) , an international e-Health, medical information technology
company, and Biomedical Synergies, Inc. ("BSI"), a privately held
healthcare consulting and software development company
headquartered in Minneapolis, Minnesota, today announced that they
have signed an agreement under which Global Med will distribute
TRACS4Life(TM) tissue tracking software. BSI specializes in human
tissue/implant tracking management software for the medical
industry. Terms of the agreement were not disclosed. (Logo:
http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO)
TRACS4Life is a best-of-breed tissue tracking software application
for hospitals and surgery centers. Built on Microsoft(R) products,
TRACS4Life meets and exceeds the Joint Commission tissue management
requirements by streamlining the investigations of worst case
scenarios, adverse reactions and product recalls. TRACS4Life uses
manufacturers' barcodes to track and trace human tissue products
and to track non-biologic implants from their entrance into a
facility through final disposition. Historically, there has been
little standardization and even less coordination of the handling
of human tissue products within healthcare facilities. Currently,
most facilities utilize a manual tissue-tracking system, which is
time consuming at best, inefficient at least, and rife with
opportunities for human error. This decentralized tracking method
translates into increased times to process a recall and to
investigate an adverse event. One hospital recently shared that
their time to manually process a recall of only seven tissue
products was over two months. This example provides clear insight
into how a manual tissue tracking system contributes to substandard
patient care, increased facility liability, inefficient clinical
operations, lack of regulatory compliance and diminished patient
outcomes. Biomedical Synergies, Inc. was founded by tissue and
blood banking experts who offer unparalleled subject matter
expertise to augment their software application, a critical
differentiation in the marketplace today. One of the founders of
BSI, who has contributed much of the intellectual property into the
software, is Duke Kasprisin, M.D. Dr. Kasprisin is the past
President of the American Association of Tissue Banks (AATB) and
was formerly the Chief Medical Officer of the American Red Cross
Transplantation Services. BSI's proven tissue tracking software and
business practices assist hospitals with biologic and non-biologic
implant product issues, regulatory compliance questions and process
inquiries. BSI partners with facilities to develop compliance
infrastructure through Standard Operating Procedures (SOPs), proper
organizational structure and software that is designed to increase
patient safety, reduce risk and streamline workflows. Chairman and
CEO of Global Med Technologies, Inc., Michael I. Ruxin, M.D.,
stated, "We are pleased to partner with Biomedical Synergies and
their extraordinary team. As a leading provider of blood banking
software and services, Global Med has seen first hand the expansion
of the blood bank's responsibility for the administration and
oversight of human tissue and cellular therapy products. To meet
the needs of our customers worldwide, Global Med will now offer an
additional mechanism to decrease the liability for hospitals and
accomplish tissue/implant tracking management more effectively and
expeditiously." Dr. Ruxin continued, "Global Med's strategy to
expand its offerings and grow our revenue base through a mutually
beneficial partnership is a win-win for Biomedical Synergies, our
customers and the Global Med Family of Companies." Global Med will
actively promote TRACS4Life to the healthcare marketplace through
its direct sales force. This mutually beneficial arrangement will
greatly expand the coverage of BSI's current sales force, allow
greater market penetration of TRACS4Life and serve the needs of
both Global Med and Biomedical Synergies' customers and ultimately,
and most importantly, help improve patient safety. Paul Kozloski,
President and CEO of Biomedical Synergies, Inc., commented, "This
is an exceptional opportunity for Biomedical Synergies to partner
with a premier blood banking software company. It offers hospitals
the expertise of two naturally synergistic processes and the result
directly affects patient outcomes in a highly beneficial manner.
Presbyterian/St. Luke's Medical Center in Denver, Colorado,
Christiana Care Health System in 4 sites throughout Delaware, and
Indiana Orthopaedic Hospital in Indianapolis, Indiana, are among
our valued customers who have implemented TRACS4Life and have
immediately realized regulatory compliance, reduced hospital
liability and have received a return on their investment through
more efficient inventory management. In addition, we are delighted
to announce the successful evaluation of TRACS4Life at Brooke Army
Medical Center (BAMC) in San Antonio, TX and look forward to a
long-standing relationship with them." About Biomedical Synergies,
Inc. Biomedical Synergies, Inc. (BSI) is a healthcare consulting
and software development firm headquartered in Minneapolis,
Minnesota, focused on the human tissue industry and founded by
tissue and blood industry experts. Utilizing TRACS4Life, BSI's
patent pending tissue and implant management software, BSI provides
products and services to hospitals nationwide pertaining to the
management of human tissue, associated surgical implants and
manufactured tissue products in their facilities. The combination
of BSI's service offerings and TRACS4Life software allow hospitals
to navigate the pitfalls of regulatory compliance, thereby offering
a 360° solution to tissue management. For more information about
Biomedical Synergies' products and services, please call
317-842-6502 or visit http://www.biomedicalsynergies.com/ or
http://www.tracs4life.com/. About Global Med Technologies(R), Inc.
Global Med Technologies, Inc. is an international medical software
company which develops regulated and non-regulated software
products and services for the healthcare industry. As a leading
provider of blood and laboratory software applications and
services, Global Med's products are deployed in 20 countries and
serve over 1,600 transfusion centers, blood banks and laboratories.
Global Med's U.S. division, Wyndgate Technologies(R), provides
Vein-to-Vein(R) tracking through its Donor Doc(TM), SafeTrace(R),
SafeTrace Tx(R) and ElDorado Donor(TM) software products. Each
year, Wyndgate's products and services manage more than eight
million blood components, representing over 27% of the U.S. blood
supply. Global Med's European subsidiary, Inlog, SA, is a leading
provider of donor center and transfusion management systems as well
as cellular therapy software, laboratory information systems and
quality assurance medical software systems internationally. Inlog's
products include EdgeBlood*, EdgeTrack*, EdgeCell, EdgeLab and
SAPANET. Global Med's U.S. division, eDonor(R), provides a
web-based donor relationship management system that integrates
recruitment, scheduling, retention and fulfillment for national as
well as local community blood centers and hospitals. eDonor's
products and services are designed to complement Global Med's
strong line of international blood management and laboratory
information software and service solutions. Global Med's U.S.
subsidiary, PeopleMed(R), Inc., provides cost-effective customized
software validation, consulting and compliance solutions to
hospitals and donor centers. For more information about Global
Med's products and services, please call 800-996-3428 or visit
http://www.globalmedtech.com/, http://www.peoplemed.com/,
http://www.inlog.com/, http://www.edonor.com/, and
http://www.wyndgate.com/. *FDA 510(k) clearance required prior to
sales in the U.S. This news release may include statements that
constitute forward-looking statements, usually containing the words
"believe," "estimate," "project," "expects" or similar expressions.
These statements are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. By making these
forward-looking statements, the Company undertakes no obligation to
update these statements for revisions or changes after the date of
this news release.
http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO
http://photoarchive.ap.org/ DATASOURCE: Global Med Technologies(R),
Inc. CONTACT: Michael I. Ruxin, M.D., of Global Med
Technologies(R), Inc., +1-303-238-2000, ; or Jeff Winstead, SVP,
Business Development of Biomedical Synergies, Inc.,
+1-317-842-6502; or Investors, Paul Holm, President of portfolio
pr, +1-212-888-4570, Web Site: htp://www.biomedicalsynergies.com
http://www.globalmedtech.com/ http://www.tracs4life.com/
Copyright